



## CORRECTION

# Correction: Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy

Can Liu<sup>1</sup>, Hua He<sup>1,2</sup>, Xiaobing Li<sup>1,3</sup>, Maureen A. Su<sup>4</sup> and Yanguang Cao<sup>1,5</sup>

*British Journal of Cancer* (2019) 120:772; <https://doi.org/10.1038/s41416-019-0418-5>

**Correction to:** *British Journal of Cancer* (2019) **120**, 346–355; <https://doi.org/10.1038/s41416-018-0363-8>; [www.bjcancer.com](http://www.bjcancer.com); published online 27 December 2018.

Since the publication of this paper, the authors noticed that the funding information for Maureen A. Su was not included.

Therefore the authors would like to add the following information to the Acknowledgements section:

### ACKNOWLEDGEMENTS

M.A.S. receives funding from Department of Defense and Parker Institute for Cancer Immunotherapy.

<sup>1</sup>Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; <sup>2</sup>School of Pharmacy, China Pharmaceutical University, 210009 Nanjing, Jiangsu, China; <sup>3</sup>Department of Pharmacy, Shengjing Hospital of China Medical University, 110004 Shenyang, Liaoning, China; <sup>4</sup>Department of Microbiology, Immunology and Medical Genetics (MIMG) and Pediatrics, University of California, Los Angeles, CA 90095, USA and <sup>5</sup>Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA  
Correspondence: Yanguang Cao ([yanguang@email.unc.edu](mailto:yanguang@email.unc.edu))